Shanghai Research Institute of Acupuncture and Meridian
Shanghai, China
Location status: Recruiting
NCT Number: NCT06553053
The aim of this study was to further improve the clinical efficacy of acupuncture in delaying the clinical recurrence of CD and to explore the efficacy mechanism of acupuncture efficacy enhancement.
Interested in participating?
Request Info16 year–75 year
All sexes
Interventional
Not applicable
Shanghai, China
Location status: Recruiting
Acupuncture has been proven to be an effective and safe treatment for CD. In this trial, based on previous studies, which mainly treated CD from the perspective of spleen and stomach tonification, we explored the therapeutic effect of acupuncture in treating CD from the perspective of tonifying the Shaoyang pivot mechanism to enhance the therapeutic effect.Brain-gut axis dysfunction is one of the important pathogenic mechanisms of CD. This trial attempted to explore the therapeutic targets and efficacy mechanisms of acupuncture to enhance CD by analysing brain-gut axis multi-pathway indicators.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patients receiving acupuncture and mild moxibustion, whom were treated 2 times per week for 12 weeks and followed up for 40 weeks. The first group of acupoints is that CV4 and Bilateral ST37, SP6, SP4, KI3, LI11, SJ4 and GB26 were selected for acupuncture and CV12 and bilateral ST36 and GB41 were selected for moxibustion. The second group of acupoints is that CV12 and Bilateral ST36, GB41, SP4, KI3, LI11, SJ4 and GB26 were selected for acupuncture and CV4 and bilateral SP6 and GB34 were selected for moxibustion. These two groups are alternate. After deqi sensation was even reinforcing and reducing. The surface temperature of acupoints was maintained at 43℃± 1℃ for moxibustion. During each treatment, acupuncture and mild moxibustion are performed simultaneously, both lasting for 30 minutes.
Patients receiving acupuncture and mild moxibustion, whom were treated 2 times per week for 12 weeks and followed up for 40 weeks. The first group of acupoints is that CV4 and Bilateral ST37, SP6, SP4, KI3 and LI11 were selected for acupuncture and CV12 and bilateral ST36 were selected for moxibustion. The second group of acupoints is that CV12 and Bilateral ST36, SP4, KI3 and LI11 were selected for acupuncture and CV4 and bilateral SP6 were selected for moxibustion. These two groups are alternate. After deqi sensation was even reinforcing and reducing. The surface temperature of acupoints was maintained at 43℃± 1℃ for moxibustion. During each treatment, acupuncture and mild moxibustion are performed simultaneously, both lasting for 30 minutes.
Time frame: Week 52
Defined as CDAI > 150 and increase ≥ 70 points, or emergency, hospitalization and surgical events due to worsening of CD conditions, or need to adjust drug to control disease condition.
Time frame: Week 52
Total number of recurrences. The median number will be counted for both groups.
Time frame: Week 52
Time to first recurrence will be counted for both groups.
Time frame: Week 0, 6, 12, 24, 36 and 52
The mean change in CDAI from baseline. The higher the score, the worse the condition. Greater than 0, no upper limit.
Time frame: Week 0, 6, 12, 24, 36 and 52
The outcome is measured by level of abdominal pain (visual analogue scale, VAS) and number of diarrhoea in the past week.
Time frame: Week 0, 6, 12, 24, 36 and 52
serum C-reactive protein (CRP)
Time frame: Week 0, 6, 12, 24, 36 and 52
erythrocyte sedimentation rate (ESR)
Time frame: Week 0, 6, 12, 24, 36 and 52
platelet count (PLT)
Time frame: Week 0, 12, 24, 36 and 52
The mean change in IBDQ from baseline. The higher the score, the worse the condition.The score is range from 32 to 224.
Time frame: Week 0, 12, 24, 36 and 52
The mean change in HADS from baseline. The higher the score, the more serious the disease. The depression and anxiety score is range from 0 to 21.
Time frame: Week 0, 12, 24, 36 and 52
The mean change in FACIT-F from baseline. The higher the score, the worse the condition. The score range from 0 to 52.
Time frame: Week 0 and 52
measured by colonoscopy (SES-CD score) or small bowel MR (MaRIA score)
Time frame: Week 0
measured by acupuncture treatment effectiveness expectation questionnaire
Time frame: Week 6 and 12
measured by patients guessing their grouping
Time frame: Week 0 and 12
Gray matter structure of the brain,functional connectivity and network properties of brain networks and local activity in brain regions were measured in an attempt to analyze the correlation between changes in these indicators after acupuncture intervention and the efficacy of acupuncture.
Time frame: Week 0 and 12
Salivary cortisol is measured by ELISA to analyze effect of acupuncture on HPA axis function.
Time frame: Week 0 and 12
α-Salivary Amylase is measured by ELISA to analyze effect of acupuncture on HPA axis function.
Time frame: Week 0 and 12
Serum cortisol is measured by ELISA to analyze effect of acupuncture on HPA axis function.
Time frame: Week 0 and 12
The effect of acupuncture on autonomic function was recorded by DMS300-4AL.
Time frame: Week 0 and 12
Intestinal inflammation levels are measured by C-reactive protein and plasma concentrations of tumour necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and IL-6.
Time frame: Week 0 and 12
Intestinal mucosal barrier function are measured by concentrations of lipopolysaccharide (LPS), Diamine oxidase (DAO) and D-lactate.
Contact information is provided by the study sponsor or research team.
Shanghai Institute of Acupuncture, Moxibustion and Meridian
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05599347
Biological Substance; Adverse Effect, Crohn Disease
Beersheba, Israel
View Trial DetailsNCT07012395
Colitis, Colitis, Ulcerative
Canoga Park, California, United States
View Trial DetailsNCT07456566
Colitis, Colitis, Ulcerative
Ann Arbor, Michigan, United States
View Trial DetailsNCT06188793
Digestive System Diseases, Gastroenteritis
Ann Arbor, Michigan, United States
View Trial Details